{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T07:39:23Z","timestamp":1794296363440,"version":"4.9.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-05278-3","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:05:23Z","timestamp":1763705123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Samin","family":"Sadraei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Aarabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahryar","family":"Rajai Firouzabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Alinejadfard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-0329","authenticated-orcid":false,"given":"Ida","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Ghaffari","family":"Jolfayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"10397","key":"5278_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong KL, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203\u201334.","journal-title":"Lancet"},{"key":"5278_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108086","volume":"162","author":"P Saeedi","year":"2020","unstructured":"Saeedi P, et al. Mortality attributable to diabetes in 20\u201379 years old adults, 2019 estimates: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2020;162:108086.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2_suppl","key":"5278_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","volume":"26","author":"E Dal Canto","year":"2019","unstructured":"Dal Canto E, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25\u201332.","journal-title":"Eur J Prev Cardiol"},{"issue":"9529","key":"5278_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(06)68967-8","volume":"368","author":"GL Booth","year":"2006","unstructured":"Booth GL, et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006;368(9529):29\u201336.","journal-title":"Lancet"},{"issue":"1","key":"5278_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/XCE.0000000000000116","volume":"6","author":"W Fan","year":"2017","unstructured":"Fan W. Epidemiology in diabetes mellitus and cardiovascular disease. Cardiovasc Endocrinol. 2017;6(1):8\u201316.","journal-title":"Cardiovasc Endocrinol"},{"issue":"7","key":"5278_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jacc.2017.07.001","volume":"70","author":"JD Newman","year":"2017","unstructured":"Newman JD, et al. Primary prevention of cardiovascular disease in diabetes mellitus. J Am Coll Cardiol. 2017;70(7):883\u201393.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"5278_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13098-023-01015-y","volume":"15","author":"X Jiao","year":"2023","unstructured":"Jiao X, et al. HbA1c is a predictive factor of severe coronary stenosis and major adverse cardiovascular events in patients with both type 2 diabetes and coronary heart disease. Diabetol Metab Syndr. 2023;15(1):50.","journal-title":"Diabetol Metab Syndr"},{"issue":"10","key":"5278_CR8","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","volume":"298","author":"S Singh","year":"2007","unstructured":"Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with RosiglitazoneA meta-analysis. JAMA. 2007;298(10):1189\u201395.","journal-title":"JAMA"},{"issue":"14","key":"5278_CR9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"4","key":"5278_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.pcad.2019.07.005","volume":"62","author":"V Garg","year":"2019","unstructured":"Garg V, Verma S, Connelly K. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog Cardiovasc Dis. 2019;62(4):349\u201357.","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"5278_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12325-020-01548-y","volume":"38","author":"A Shi","year":"2021","unstructured":"Shi A, et al. Pharmacokinetics, safety and tolerability of once-weekly subcutaneous semaglutide in healthy Chinese subjects: a double-blind, phase 1, randomized controlled trial. Adv Ther. 2021;38(1):550\u201361.","journal-title":"Adv Ther"},{"issue":"4","key":"5278_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2019.107520","volume":"34","author":"SL Anderson","year":"2020","unstructured":"Anderson SL, Beutel TR, Trujillo JM. Oral semaglutide in type 2 diabetes. J Diabetes Complications. 2020;34(4):107520.","journal-title":"J Diabetes Complications"},{"issue":"9","key":"5278_CR13","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1111\/dom.13361","volume":"20","author":"P Andreadis","year":"2018","unstructured":"Andreadis P, et al. Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(9):2255\u201363.","journal-title":"Diabetes Obes Metab"},{"key":"5278_CR14","volume":"36","author":"H Yaribeygi","year":"2024","unstructured":"Yaribeygi H, et al. Anti-inflammatory benefits of semaglutide: state of the art. J Clin Transl Endocrinol. 2024;36:100340.","journal-title":"J Clin Transl Endocrinol"},{"key":"5278_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110196","volume":"119","author":"X Pan","year":"2023","unstructured":"Pan X, et al. Semaglutide alleviates inflammation-induced endothelial progenitor cells injury by inhibiting MiR-155 expression in macrophage exosomes. Int Immunopharmacol. 2023;119:110196.","journal-title":"Int Immunopharmacol"},{"key":"5278_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645563","volume":"12","author":"MM Smits","year":"2021","unstructured":"Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021;12:645563.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"5278_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-020-01070-z","volume":"19","author":"OM Alfayez","year":"2020","unstructured":"Alfayez OM, et al. Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis. Cardiovasc Diabetol. 2020;19(1):96.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"5278_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.pcd.2020.08.017","volume":"15","author":"X-B Wei","year":"2021","unstructured":"Wei X-B, et al. Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: a network meta-analysis of large randomized trials. Prim Care Diabetes. 2021;15(2):208\u201311.","journal-title":"Prim Care Diabetes"},{"key":"5278_CR19","volume":"372","author":"JP Matthew","year":"2021","unstructured":"Matthew JP, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"11","key":"5278_CR20","first-page":"e563","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140(11):e563\u201395.","journal-title":"Circulation"},{"issue":"34","key":"5278_CR21","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"key":"5278_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"5278_CR23","doi-asserted-by":"crossref","unstructured":"McGuinness, L.A. and J.P.T. Higgins, Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Research Synthesis Methods, 2020. n\/a(n\/a).","DOI":"10.1002\/jrsm.1411"},{"key":"5278_CR24","unstructured":"Chochrane Handbook, Chapter 9.5.2 : Identifying and measuring heterogeneity."},{"issue":"19","key":"5278_CR25","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"9","key":"5278_CR26","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"24","key":"5278_CR27","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"key":"5278_CR28","doi-asserted-by":"crossref","unstructured":"Mahaffey, K.W., et al., Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. Eur Heart J. 2025;46(12):1096\u2013108.","DOI":"10.1093\/eurheartj\/ehae613"},{"issue":"2","key":"5278_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"key":"5278_CR30","doi-asserted-by":"crossref","unstructured":"Association, A.D., 1. Improving care and promoting health in populations: Standards of Medical Care in Diabetes\u20142021. Diabetes Care, 2021. 44(Supplement_1): p. S7-S14.","DOI":"10.2337\/dc21-S001"},{"key":"5278_CR31","doi-asserted-by":"crossref","unstructured":"Husain M, et al. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovasc Diabetol. 2020;19:1\u201311.","DOI":"10.1186\/s12933-020-01106-4"},{"issue":"1","key":"5278_CR32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12933-023-01949-7","volume":"22","author":"P Rossing","year":"2023","unstructured":"Rossing P, et al. Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis. Cardiovasc Diabetol. 2023;22(1):220.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"5278_CR33","first-page":"844","volume":"3","author":"G Rakipovski","year":"2018","unstructured":"Rakipovski G, et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE\u2212\/\u2212 and LDLr\u2212\/\u2212 mice by a mechanism that includes inflammatory pathways. JACC: Basic to Translational Science. 2018;3(6):844\u201357.","journal-title":"JACC: Basic to Translational Science"},{"issue":"6","key":"5278_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/2040622314546125","volume":"5","author":"CR Triggle","year":"2014","unstructured":"Triggle CR, Ding H. Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis. 2014;5(6):245\u201368.","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"5278_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12933-021-01417-0","volume":"20","author":"JFK Saraiva","year":"2021","unstructured":"Saraiva JFK, Franco D. Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients. Cardiovasc Diabetol. 2021;20(1):235.","journal-title":"Cardiovasc Diabetol"},{"key":"5278_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01520-3","author":"S Wang","year":"2024","unstructured":"Wang S, et al. Glycemic control, weight management, cardiovascular safety, and cost-effectiveness of semaglutide for patients with type 2 diabetes mellitus: a rapid review and meta-analysis of real-world studies. Diabetes Ther. 2024. https:\/\/doi.org\/10.1007\/s13300-023-01520-3.","journal-title":"Diabetes Ther"},{"issue":"30","key":"5278_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026431","volume":"100","author":"X-Y Duan","year":"2021","unstructured":"Duan X-Y, Liu S-Y, Yin D-G. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: a network meta-analysis based on cardiovascular or renal outcome trials. Medicine (Baltimore). 2021;100(30):e26431.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"5278_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","volume":"6","author":"MA Bethel","year":"2018","unstructured":"Bethel MA, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105\u201313.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5278_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.935823","volume":"13","author":"X Gao","year":"2022","unstructured":"Gao X, et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13:935823.","journal-title":"Front Pharmacol"},{"key":"5278_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:440904.","journal-title":"Front Endocrinol"},{"issue":"25","key":"5278_CR41","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1161\/CIRCULATIONAHA.106.655688","volume":"114","author":"VJ Dzau","year":"2006","unstructured":"Dzau VJ, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114(25):2850\u201370.","journal-title":"Circulation"},{"issue":"10","key":"5278_CR42","first-page":"1298","volume":"8","author":"C Withaar","year":"2023","unstructured":"Withaar C, et al. The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF. Basic Transl Sci. 2023;8(10):1298\u2013314.","journal-title":"Basic Transl Sci"},{"issue":"15","key":"5278_CR43","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jama.2019.2942","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466\u201380.","journal-title":"JAMA"},{"issue":"9","key":"5278_CR44","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724\u201332.","journal-title":"Diabetes Care"},{"issue":"12","key":"5278_CR45","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.2337\/dc19-0898","volume":"42","author":"B Zinman","year":"2019","unstructured":"Zinman B, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262\u201371.","journal-title":"Diabetes Care"},{"key":"5278_CR46","doi-asserted-by":"publisher","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, et al. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol. 2022;13:1043789.","journal-title":"Front Endocrinol"},{"issue":"2","key":"5278_CR47","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/ph17020199","volume":"17","author":"WA Aldhaleei","year":"2024","unstructured":"Aldhaleei WA, Abegaz TM, Bhagavathula AS. Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the National Institutes of Health all of us cohort. Pharmaceuticals. 2024;17(2):199.","journal-title":"Pharmaceuticals"},{"key":"5278_CR48","doi-asserted-by":"crossref","unstructured":"Urschel, K. and I. Cicha, TNF-\u03b1 in the cardiovascular system: from physiology to therapy. Int J Interferon Cytokine Mediator Res. 2015: p. 9\u201325.","DOI":"10.2147\/IJICMR.S64894"},{"key":"5278_CR49","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00011-020-01382-6","volume":"69","author":"A Elyasi","year":"2020","unstructured":"Elyasi A, et al. The role of interferon-\u03b3 in cardiovascular disease: an update. Inflamm Res. 2020;69:975\u201388.","journal-title":"Inflamm Res"},{"issue":"1","key":"5278_CR50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12933-023-01800-z","volume":"22","author":"S Piccini","year":"2023","unstructured":"Piccini S, et al. Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study. Cardiovasc Diabetol. 2023;22(1):69.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"5278_CR51","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/jdi.14265","volume":"15","author":"T Horii","year":"2024","unstructured":"Horii T, et al. Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data. J Diabetes Investig. 2024;15(11):1578\u201384.","journal-title":"J Diabetes Investig"},{"issue":"2","key":"5278_CR52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/jama.2024.22284","volume":"333","author":"SS Khan","year":"2025","unstructured":"Khan SS, Ndumele CE, Kazi DS. Discontinuation of glucagon-like peptide-1 receptor agonists. JAMA. 2025;333(2):113\u20134.","journal-title":"JAMA"},{"issue":"5","key":"5278_CR53","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s13300-021-01053-7","volume":"12","author":"C Uzoigwe","year":"2021","unstructured":"Uzoigwe C, et al. Semaglutide once-weekly persistence and adherence versus other GLP-1 RAs in patients with type 2 diabetes in a US real-world setting. Diabetes Ther. 2021;12(5):1475\u201389.","journal-title":"Diabetes Ther"},{"issue":"8","key":"5278_CR54","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1007\/s00125-025-06439-x","volume":"68","author":"C-E Lim","year":"2025","unstructured":"Lim C-E, et al. Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes. Diabetologia. 2025;68(8):1680\u201395.","journal-title":"Diabetologia"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-05278-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T19:03:16Z","timestamp":1767034996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-025-05278-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5278"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-05278-3","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"881"}}